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40-word summary: 
A study of viral load, viral shedding, and immune response in 37 cases of MERS-
coronavirus infection. Virus was not eliminated from the respiratory tract upon 
development of neutralizing serum antibodies. Vaccination strategies should not be 
restricted to eliciting neutralizing antibodies.  at R
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Abstract 
Background 
The MERS coronavirus causes isolated cases and outbreaks of severe respiratory 
disease. Essential features of the natural history of disease are poorly understood.  
Methods 
We studied 37 adult patients infected with MERS-CoV for viral load in the lower and 
upper respiratory tract (LRT and URT), blood, stool, and urine. Antibodies and serum 
neutralizing activities were determined over the course of disease.  
Results 
199 LRT samples collected during the 3 weeks following diagnosis yielded virus RNA in 
93% of tests. Average (maximum) viral loads were 5x106 (6x1010) copies per mL. Viral 
loads (positive detection frequencies) in 84 URT samples were 1.9x104 cop/mL (47.6%). 
33% of all 108 sera tested yielded viral RNA. Only 14.6% of stool and 2.4% of urine 
samples yielded viral RNA. All seroconversions occurred during the first 2 weeks after 
diagnosis, which corresponds to the 2nd and 3rd week after symptoms onset. IgM 
detection provided no advantage in sensitivity over IgG detection. All surviving patients, 
but only slightly more than half of all fatal cases, produced IgG and neutralizing 
antibodies. The levels of IgG and neutralizing antibodies were weakly and inversely 
correlated with LRT viral loads. Presence of antibodies did not lead to the elimination of 
virus from LRT.  
Conclusions 
The timing and intensity of respiratory viral shedding in MERS patients closely matches 
that of Severe Acute Respiratory Syndrome (SARS) patients. Blood viral RNA does not 
seem to be infectious. Extra-pulmonary loci of virus replication seem possible. 
Neutralizing antibodies do not suffice to clear the infection.  
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Background 
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first isolated in 
2012 in Saudi Arabia [1]. Since 2012, at least 1,595 laboratory-confirmed cases of MERS-
CoV infection, mostly with respiratory tract illness, have been reported. 571 of these 
were fatal [2]. Known cases and outbreaks have been linked to countries in the Arabian 
peninsula [3]. Large nosocomial outbreaks, such as in Jeddah/KSA in 2014 and the 
Republic of Korea in 2015, have demonstrated the potential of the virus to spread in 
health care settings [4-6].  
 
Due to the sporadic nature of the disease, with cases and small outbreaks distributed 
over a wide geographic area, investigation of the natural history of infection has been 
limited. Except individual case descriptions, chronological data summarizing the main 
viral diagnostic parameters, such as viral load or antibodies, are lacking. Better 
knowledge of the kinetics of viral shedding from different body regions could help 
prevent nosocomial transmission and inform clinical management. Knowledge of 
serological features, such as the kinetics of antibody production, could guide decisions 
regarding diagnostic protocols and provide essential information regarding immunity 
and virus elimination. Quantitative data, such as viral loads and antibody titers, could 
enable comparisons with related diseases. In particular with SARS, for which studies of 
natural history were conducted in the aftermath of the 2002-2003 epidemic [7].   
   
Materials and Methods 
Patients and samples 
Patients were seen during a hospital-associated outbreak between March 5th and May 
1st, 2014. There was no prospective planning of statistical power. Patients were selected 
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for MERS-CoV testing by RT-PCR based on general clinical condition, oxygen saturation, 
and their need for invasive or non-invasive ventilation. Samples of patients who tested 
positive were taken at least daily, starting from 0 to 7 days after initial submission of 
samples for MERS-CoV diagnosis. The day of the first sample tested positive in RT-PCR 
was defined as the day of diagnosis. The mean delay between first positive sampling and 
return of laboratory results was 3 days. Stored samples, for retrospective analysis, were 
not available.  
Specimens were taken from tracheal secretions via suction catheters, from the throat 
and the eyes using sterile swabs, and from urine and stool via sterile containers. 
Baseline information on enrolled patients is provided in Supplementary Table S1. 
Institutional review board approval was obtained from the Research Ethics Committee 
at Prince Sultan Military Medical City. 
 
MERS-CoV RT-PCR testing 
Real-time RT-PCR was performed on RNA extracts using the upE and ORF1A target 
genes as described in [8, 9]. Raw RNA concentrations were transformed to absolute viral 
loads by conversion factors, according to sample type (Supplementary Table S2).  
 
MERS-CoV isolation in cell culture 
Virus isolation, with increased sensitivity via the use of CaCo2 human colon carcinoma 
cells, was performed as described in [10].  
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MERS CoV serology 
Recombinant enzyme-linked immunosorbent assay (ELISA) 
A recombinant ELISA assay (Anti-MERS-CoV ELISA IgG, Euroimmun, Lübeck/Germany) 
was based on soluble MERS-CoV spike protein S1 domain expressed in HEK-293T cells 
[11]. The test was conducted as described previously [12, 13]. Sera were tested twice 
and the arithmetic mean of the two measurements was used.  
 
IgM immunofluorescence assay (IgM-IFA)  
Detection of IgM antibodies was done using immunofluorescence slides carrying Vero 
cells infected with full MERS-CoV, as described in Corman et al. [9]. These were 
converted into a homogenous reagent format by an in vitro diagnostics manufacturer 
(Anti-MERS-CoV-IIFT; Euroimmun). All sera were depleted of IgG antibodies using 
Eurosorb (Euroimmun) reagent according to manufacturer instructions.  
 
Serum neutralization assay 
A MERS-CoV microneutralization test (NT) was performed as described in [13-15]. 
Predilution before setting up log2-dilution series was 1:10, defining 1:20 as the lowest 
possible significant titer for categorizing a sample as positive.      
 
Statistical analyses 
Statistical analyses were done with the help of the SPSS software (version 22). In all 
cases, correlation analyses and preliminary multiple regression analyses were 
conducted to exclude confounding due to patient age or disease duration. 
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Results 
 
Patients’ characteristics 
 
To determine kinetic virological parameters in MERS-CoV infection, we followed 37 
hospitalized patients. Mean age was 63 years (range 24-90 years). 73% of patients were 
male. MERS-CoV infection had been established in all cases by RT-PCR. 65% of all 
patients died during the course of study.  
 
Sequencing of full or partial genomes from 35 of the study patients revealed the 
existence of at least 6 closely-related virus lineages (Supplementary Figure S1 and 
Supplementary Table S1). Some sequences had already been seen in an earlier study 
[5]. Patients belonged to at least 3 nosocomial transmission clusters. Three cases could 
not be associated with clusters. 
 
At time of positive diagnosis, patients had spent 11 days in hospital on average, with a 
maximum of 108 days. Only 20 of the 37 patients had been hospitalized for less than a 
week. Because of the unresolved timing of transmission events in nosocomial clusters 
and the existence of co-morbidities in most patients, it was impossible to determine the 
day of onset of symptoms in the majority of patients. Unambiguous knowledge of the 
day of onset of symptoms was available for only 9 patients. Mean and median duration 
between symptom onset and admission was 3 days (range, 0-8 days). In these 9 cases, 
mean and median duration between onset and diagnosis was 8 days (range, 1-16 days). 
The mean age of the 9 cases was not significantly different from the mean age of all 
patients under study. To provide a common point of reference in the clinical course of all 
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patients, the day of diagnosis (day of first RT-PCR positive sample) was defined as day 
zero in the subsequent analyses.  
 
823 specimens from the 37 patients were tested, including 661 tests for viral load in 6 
different sample categories (Supplementary Table S2). Because of the variable latency 
between diagnosis and enrolment, clinical samples were not evenly distributed over 
patients’ courses of disease (Supplementary Figure S2).   
 
Cross-sectional virus RNA detection and courses of viral load 
Absolute viral RNA concentrations and positive proportion of samples were determined 
in 661 samples. Data are illustrated in Figure 1 and Supplementary Table S2. LRT 
samples had the highest viral loads, up to 6.3x1010 copies/mL (mean 5.01x106). Average 
viral loads in all other sample types were significantly lower (two-tailed T-test, 
p<0.0001 for all comparisons). Virus isolation trials using the six stool samples with the 
highest RNA concentration had negative outcomes.  
 
Almost half of all sera showed detectable viral loads during the first week after diagnosis 
(25 of 51 sera tested). Virus isolation from 20 viraemic serum samples (10 with, and 10 
without neutralizing antibodies) failed, in spite of a highly optimized protocol [10]. 
There was an inverse correlation between in vitro serum neutralization activity and 
viremia in 45 sera (Pearson’s R=-0.31, p<0.03). However, viral RNA and neutralizing 
antibodies were co-detected in several cases, suggesting that the detected viral RNA may 
only in part represent infectious virions (Figure 2A). Concentrations of RNA in serum 
did not correlate significantly with those in LRT samples collected on the same day 
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(n=31 pairs of serum and LRT samples; Spearman’s correlation, p=0.08). Data are shown 
in Figure 2B.  
 
Distributions of average LRT viral load per patient were summarized in three 
subsequent time windows, as shown in Figure 3. In particular, during the first five days 
after diagnosis, average viral loads were not normally distributed but had a skewed 
distribution with a preponderance of patients with high viral load. Of note, the 17 
patients in the two highest viral load categories (right-most columns in the top panel in 
Figure 3) did not show a significantly increased proportion of fatal outcomes (chi-
squared test, p=0.12).  
 
The average viral load during the first week after diagnosis was 5x107 copies/mL in fatal 
cases and 3.9x106 copies/mL in survivors (2-tailed T-test, p<0.007). Divergence of viral 
loads between survivors and fatal cases was more pronounced in the second week 
(1.6x105 and 7.8x106 copies/mL, respectively, p<0.0006).   
 
Time course of antibody production 
Serological courses could be followed for 35 patients. Almost half of these (n=17) were 
already reactive (via ELISA) on the day of diagnosis. Among 27 patients with complete 
serological follow-up during the first week after diagnosis, 89% (n=24) had antibodies 
by end of the week in both ELISA and neutralization tests. 18 of these patients tested 
positive for IgM by IFA (titers >1:10) by end of the week. Only one of the IgM-positive 
patients did not have a concomitant positive ELISA result by end of the week. All of the 
12 patients with 2 weeks of serological follow-up seroconverted (ELISA and 
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neutralization tests). Eleven of these 12 patients developed IgM detectable by IFA. 
Antibody kinetics averaged over all samples and tests are summarized in Figure 4.  
 
Information on outcome was available for 34 patients with serological follow-up. All 12 
patients who survived their infection showed seroconversion (ELISA and NT tests) 
during the first week. All developed IgM antibodies concomitantly. Among 22 fatal cases, 
14 showed seroconversion by ELISA prior to death, the latest seroconversion occurring 
by day 11 post-diagnosis. Twelve of 22 fatal cases developed neutralizing antibodies and 
11 developed detectable IgM. Antibody levels (ELISA OD and log2 NT titers) during the 
first week after diagnosis were not significantly different between surviving and fatal 
cases (2-tailed T-test, p=0.8). During the second week after diagnosis, the average ELISA 
OD values in survivors were significantly higher than in fatal cases (2.9 vs. 2.1, 2-tailed 
T-test, p<0.02). Also, average NT titers were higher in survivors during week 2, but with 
less significant discrimination (27.5 vs. 25.4 in survivors and fatal cases, 2-tailed T-test, 
p<0.06).   
 
Correlation of ELISA antibodies, NT titers, and viral loads 
ELISA OD values and log2 NT titers were compared against log10 viral loads in LRT 
samples. From 30 patients, ELISA and viral load data were available based on matched 
serum and respiratory tract samples taken on the same days (198 matched data pairs, 
covering days 0 to 17 post-diagnosis). Because of workload and biosafety, the number of 
NT assays had to be restricted. However, combined ELISA, NT, and viral load data were 
available from 26 patients, with 91 matched datasets that covered days 1-17 after 
diagnosis. Supplementary Figure 3 summarizes the distribution of matched samples 
over time. Pearson’s test identified significant linear correlation between antibodies and 
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log10 viral loads [ELISA, R=-0.6; NT, R=-0.51; p<0.001 in both analyses]. However, plots 
of ELISA and NT antibody results in matched sample pairs yielded no evidence of 
mutually exclusive occurrence of virus and antibodies (Figures 5A and B).  
 
Discussion 
We studied quantitative viral excretion and serum antibody kinetics of a substantial 
group of hospitalized patients infected with MERS-CoV. The time of diagnosis chosen as 
a chronological reference point represents the time when an infection is suspected in 
hospitalized patients, or when outpatients report to hospitals due to worsening 
symptoms. Even though the day of onset was unknown in many of the studied cases, the 
presented virological courses represent the typical situation encountered during MERS 
treatment in hospital settings.  
 
By providing absolute quantitative measures of virus excretion, we can for the first time 
compare results between MERS and SARS - a disease that is now thought to have 
involved higher pandemic potential than MERS [16]. In our patients and elsewhere, the 
LRT was found to be the main source of MERS-CoV excretion [17]. Unfortunately, there 
are few data on LRT virus excretion for SARS-CoV, because endotracheal sampling was 
widely discouraged during SARS outbreaks to avoid nosocomial risks. We have shown, 
in one of the few available studies, that SARS-CoV was excreted from the LRT at mean 
concentrations of 1.2-2.8x106 copies per mL, reaching a maximum of 1010 copies per mL 
[18]. That study was conducted in a similar clinical context (a treatment center in 
Singapore) with similar timing of samples and clinical courses. Determination of viral 
load was performed by the same laboratory, using equivalent calibrators and conversion 
factors. From this comparison we can conclude that average and peak LRT viral loads in 
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MERS are equal to those in SARS [18]. More data are available for URT viral loads in 
SARS patients. Peak URT RNA concentrations can reach up to 5x105 copies per sample 
between days 7 to 10 after onset [18, 19]. The corresponding number for MERS (peaking 
at 4.1x106 copies per sample), is equivalent or higher. Also, the 47.6% proportion 
positive for MERS in URT exceeded the 38% proportion positive in 98 URT samples for 
SARS patients in Hong Kong [19].  
 
The timing of excretion is more difficult to compare, as many patients in studies on SARS 
were outpatients who entered hospital because of their SARS infection, while our MERS 
patients were mostly inpatients [20]. In SARS cases that occurred before Hong Kong 
authorities started active community contact tracing, the average time from symptom 
onset to admission was 4 to 7 days[20]. Because case definitions and diagnostics were 
well established during SARS in Hong Kong, diagnostic samples would have been taken 
immediately upon admission. This can be aligned with the timing in our study based on 
a sub-cohort of patients for whom an onset of symptoms could be reliably determined. 
In these patients, the time from onset of symptoms to the initiation of laboratory 
diagnostics (8 days) was similar to that of early Hong Kong SARS cases. The shedding 
peak in SARS patients occurred after ca. 10-12 days from symptom onset, which is very 
similar to the shedding maximum observed in our study, under the assumption that the 
day of first diagnosis in our MERS cases plausibly falls around the 8th day of symptoms 
(i.e., direct after admission) [21, 22]. In summary, neither the virus concentration nor 
the timing of respiratory shedding provide an explanation for differences in 
transmissibility between MERS-CoV and SARS-CoV. Experimental data suggest a higher 
sensitivity of MERS-CoV to respiratory epithelium-associated type I interferon, which 
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might provide a plausible explanation for its lower transmissibility in comparison with 
SARS-CoV [23]. Many other explanations are possible, however.  
 
The detection of MERS-CoV in serum is another similarity with SARS. Up to79% of 
serum samples were found to contain SARS-CoV RNA during the first week of illness, 
and around 50% during the second week [24-26]. These numbers match our 
observations for MERS. Free viraemia seems unlikely as a cause of nosocomial 
transmission of MERS, as no infectious virus was isolated from serum. There is evidence 
of SARS-CoV replicating in PBMC, macrophages, and dendritic cells, albeit at low levels 
[27-30]. In the present study, the absence of correlation of serum viral load with LRT 
viral load points to potential extra-pulmonary replication. Viremia despite the presence 
of neutralizing antibodies indicates a body region that is not accessible to neutralizing 
antibodies but which releases virus into the blood. SARS-CoV has been shown to 
replicate in several extra-pulmonary organs without evidence of tissue damage [27]. 
One organ implicated in MERS is the kidney. Kidney failure has been reported in many 
cases, and MERS-CoV was originally isolated in kidney cells which express DPP4, the 
MERS-CoV entry receptor [11]. However, earlier healthcare-associated outbreaks have 
been centered near dialysis centers and nephrology departments, and have affected 
metabolically compromised patients who are predisposed to kidney failure when 
suffering from systemic disease affecting blood pressure and circulation. While SARS-
CoV patients showed viral RNA detection rates up to 50% in urine [7, 22], we rarely 
found urine-associated MERS-CoV RNA in this study. As in SARS, kidney failure in MERS 
patients might well be explained by severe inflammatory reaction combined with the 
administration of potentially nephrotoxic drugs during intensive care [31]. 
 at R
uth Lilly M
edical Library on A
ugust 22, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
14 
 
Nevertheless, it will be highly important to conduct post mortem examinations, 
particularly of the kidney, of patients who die during acute MERS-CoV infection.  
 
A clear difference from SARS was the detection of viral RNA in stool. In SARS, the RNA 
prevalence in stool samples was so high that testing of stool was proposed as a reliable 
and sensitive way to routinely diagnose the disease [7, 22]. Active replication in the gut 
with live virus isolation has been demonstrated [32]. For MERS, we found stool-
associated RNA in only 14.6% samples, with rather low RNA concentration and had no 
success in isolating infectious virus. Based on these data, fecal excretion may not have 
played a relevant role for nosocomial spread of MERS-CoV among the patients under 
study.   
 
As in SARS, MERS-CoV nosocomial transmission was repeatedly ascribed to the potential 
of some patients to act as super-shedders or super-spreaders [6, 20]. Our analysis of 
viral loads particularly in the early acute phase of disease, supports the existence of a 
limited number of patients with extraordinarily high viral loads. As these patients were 
not more likely to die of the infection, they might not have had more severe symptoms, 
and thus might have been able to engage in social contact despite their disease.  
 
The course of MERS antibody development resembles that of SARS. Patients infected 
with SARS seroconverted during weeks 2 and 3 after onset [7]. Most of the patients 
studied here had already seroconverted during the first week after diagnosis, which 
putatively represents the second week after onset. As in SARS, IgM was not detected 
earlier than IgG, which limits its diagnostic utility, in particular when considering that 
IgM against more prevalent HCoVs may cross-react with MERS-CoV [12, 33]. With 
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current methodology, IgM testing should be restricted to cases that require proof of 
recent and overcome MERS-CoV infection.  
 
Information on the prognostic value of antibody response in SARS is less clear. In the 
present study on MERS, 36% (ELISA) and 45% (NT) of fatal cases failed to mount an 
antibody response prior to death. However, differences became apparent only in the 
second week after diagnosis, pointing to only a weak protective effect against lung 
disease. The development of antibodies in serum was not followed by a rapid 
elimination of viral RNA from the lung. Neutralizing antibodies normally include IgA 
secreted in respiratory fluids and saliva. We have recently shown that anti-MERS-CoV 
IgA is indeed secreted in respiratory fluids [10], suggesting that the development of IgA 
comes too late to confer timely reduction of viral replication in infected mucosa. Based 
on these data, vaccines against MERS-CoV should be designed so as to include and 
enhance cellular immune responses.   
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Figure legends 
 
Figure 1  
Viral loads in MERS patients. Mean viral loads in positive-testing samples per day and 
specimen type. Maximum and minimum viral loads are shown as purple and cyan lines, 
respectively. Error bars represent standard derivations. Sample numbers and 
proportion of positive samples are summarized in Supplementary Figure S2.  
 
Figure 2  
Correlation of serum viral RNA detection with neutralizing antibodies and viral 
RNA concentration in respiratory samples. A, neutralizing antibodies; B, viral RNA 
concentration in LRT samples. Columns in both panels show serum viral load. Empty 
spaces represent serum samples that tested negative for viral RNA.  
 
Figure 3  
Distribution of RNA viral loads in LRT samples in three time windows. Columns 
show viral loads for each patient averaged over the time windows indicated to the right 
of each panel. Curves represent ideal normal distributions based on sample means and 
variance. 
 
Figure 4 
Kinetics of antibody production 
The red line shows mean IgG- titer, represented as OD ratios obtained from S1-ELISA . 
The yellow line shows mean IgM-titer from an immunofluorescence test. The cyan line 
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shows virus neutralization titer.  Titers from each patient are averaged over successive 
3-day time intervals. 
 
Figure 5 
Effect of serum antibodies on LRT viral loads. This analysis is based on paired serum 
and LRT samples taken from the same patient on the same day. Antibodies are shown as 
line graphs. Viral loads in the corresponding LRT samples are shown as columns.  The 
panels show samples sorted according to increasing levels of ELISA OD ratios (A) or 
neutralizing antibody titers (B). Sample numbers for this analysis are summarized in 
Supplementary Figure S3.  
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